Angelini Group – Product Pipeline Review – 2012
Summary
Global Market Direct’s pharmaceuticals report, “Angelini Group - Product Pipeline Review - 2012” provides data on the Angelini Group’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Angelini Group’s corporate website, SEC filings, investor presentations and featured press releases, both from Angelini Group and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Current R&D Portfolio of Angelini Group; Angelini Group - Key Therapeutics; Angelini Group - Pipeline Overview and Promising Molecules; Angelini Group - News; Angelini Group - Latest Updates; Angelini Group - Pipeline; Angelini Group - Discontinued/Dormant Projects
Summary
Global Market Direct’s pharmaceuticals report, “Angelini Group - Product Pipeline Review - 2012” provides data on the Angelini Group’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Angelini Group’s corporate website, SEC filings, investor presentations and featured press releases, both from Angelini Group and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Angelini Group - Brief Angelini Group overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Angelini Group human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Angelini Group with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Angelini Group’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
- Evaluate Angelini Group’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Angelini Group in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Angelini Group’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Angelini Group.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Angelini Group and identify potential opportunities in those areas.
Current R&D Portfolio of Angelini Group; Angelini Group - Key Therapeutics; Angelini Group - Pipeline Overview and Promising Molecules; Angelini Group - News; Angelini Group - Latest Updates; Angelini Group - Pipeline; Angelini Group - Discontinued/Dormant Projects
Angelini Group Snapshot
Angelini Group Overview
Key Information
Key Facts
Angelini Group – Research and Development Overview
Key Therapeutic Areas
Angelini Group – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Angelini Group – Pipeline Products Glance
Angelini Group – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Angelini Group – Drug Profiles
AF3473
Product Description
Mechanism of Action
R&D Progress
AF3485
Product Description
Mechanism of Action
R&D Progress
GSK-3ß Inhibitor
Product Description
Mechanism of Action
R&D Progress
MCP-1/CCL2 + Selected CytoKines Productions Inhibitors
Product Description
Mechanism of Action
R&D Progress
PPARgamma Modulators
Product Description
Mechanism of Action
R&D Progress
Angelini Group – Pipeline Analysis
Angelini Group – Pipeline Products by Therapeutic Class
Angelini Group – Pipeline Products By Target
Angelini Group – Pipeline Products By Mechanism of Action
Angelini Group - Dormant Projects
Angelini Group – Company Statement
Angelini Group – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Angelini Group - Key Manufacturing Facilities
Financial Deals Landscape
Angelini Group, Deals Summary
Angelini Group, Pharmaceuticals & Healthcare, Deal Details
Partnerships
Vitaflo Scandinavia Enters Into Distribution Agreement With Angelini Group
Labopharm Forms Joint Venture With Angelini
Angelini Group Enters Into Co-Marketing Agreement With Optimer Pharma For Prulifloxacin
Gruppo Angelini Enters Into Co-Development Agreement With Labopharm
Licensing Agreements
Labopharm Enters Into Licensing Agreement With Angelini Group For OLEPTRO
Labopharm Enters Into Licensing Agreement With Angelini Group For Acetaminophen
Gruppo Angelini Enters Into Licensing Agreement With Labopharm
Labopharm Enters Into Licensing Agreement With Angelini
Helsinn Enters Into Licensing Agreement With ANGELINI FARMACEUTICA
Recordati Signs Licensing Agreement With Angelini
Acquisition
Angelini Group Acquires Faran Labs
Angelini Group Acquires Csc Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Angelini Group, Key Information
Angelini Group, Key Facts
Angelini Group – Pipeline by Indication, 2012
Angelini Group – Pipeline by Stage of Development, 2012
Angelini Group – Monotherapy Products in Pipeline, 2012
Angelini Group – Combination Treatment Modalities in Pipeline, 2012
Angelini Group – Pre-Clinical, 2012
Angelini Group – Pipeline By Therapeutic Class, 2012
Angelini Group - Pipeline By Target, 2012
Angelini Group – Pipeline Products By Mechanism of Action, 2012
Angelini Group - Dormant Developmental Projects,2012
Angelini Group, Other Locations
Angelini Group, Subsidiaries
Angelini Group, Key Manufacturing Facilities
Angelini Group, Deals Summary
Vitaflo Scandinavia Enters Into Distribution Agreement With Angelini Group
Labopharm Forms Joint Venture With Angelini
Angelini Group Enters Into Co-Marketing Agreement With Optimer Pharma For Prulifloxacin
Gruppo Angelini Enters Into Co-Development Agreement With Labopharm
Labopharm Enters Into Licensing Agreement With Angelini Group For OLEPTRO
Labopharm Enters Into Licensing Agreement With Angelini Group For Acetaminophen
Gruppo Angelini Enters Into Licensing Agreement With Labopharm
Labopharm Enters Into Licensing Agreement With Angelini
Helsinn Enters Into Licensing Agreement With ANGELINI FARMACEUTICA
Recordati Signs Licensing Agreement With Angelini
Angelini Group Acquires Faran Labs
Angelini Group Acquires Csc Pharma
LIST OF FIGURES
Angelini Group – Pipeline by Indication, 2012
Angelini Group – Pipeline by Stage of Development, 2012
Angelini Group – Monotherapy Products in Pipeline, 2012
Angelini Group – Combination Treatment Modalities in Pipeline, 2012
Angelini Group – Pipeline By Therapeutic Class, 2012
Angelini Group - Pipeline By Target, 2012
Angelini Group - Pipeline Products By Mechanism of Action, 2012
Angelini Group Overview
Key Information
Key Facts
Angelini Group – Research and Development Overview
Key Therapeutic Areas
Angelini Group – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Angelini Group – Pipeline Products Glance
Angelini Group – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Angelini Group – Drug Profiles
AF3473
Product Description
Mechanism of Action
R&D Progress
AF3485
Product Description
Mechanism of Action
R&D Progress
GSK-3ß Inhibitor
Product Description
Mechanism of Action
R&D Progress
MCP-1/CCL2 + Selected CytoKines Productions Inhibitors
Product Description
Mechanism of Action
R&D Progress
PPARgamma Modulators
Product Description
Mechanism of Action
R&D Progress
Angelini Group – Pipeline Analysis
Angelini Group – Pipeline Products by Therapeutic Class
Angelini Group – Pipeline Products By Target
Angelini Group – Pipeline Products By Mechanism of Action
Angelini Group - Dormant Projects
Angelini Group – Company Statement
Angelini Group – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Angelini Group - Key Manufacturing Facilities
Financial Deals Landscape
Angelini Group, Deals Summary
Angelini Group, Pharmaceuticals & Healthcare, Deal Details
Partnerships
Vitaflo Scandinavia Enters Into Distribution Agreement With Angelini Group
Labopharm Forms Joint Venture With Angelini
Angelini Group Enters Into Co-Marketing Agreement With Optimer Pharma For Prulifloxacin
Gruppo Angelini Enters Into Co-Development Agreement With Labopharm
Licensing Agreements
Labopharm Enters Into Licensing Agreement With Angelini Group For OLEPTRO
Labopharm Enters Into Licensing Agreement With Angelini Group For Acetaminophen
Gruppo Angelini Enters Into Licensing Agreement With Labopharm
Labopharm Enters Into Licensing Agreement With Angelini
Helsinn Enters Into Licensing Agreement With ANGELINI FARMACEUTICA
Recordati Signs Licensing Agreement With Angelini
Acquisition
Angelini Group Acquires Faran Labs
Angelini Group Acquires Csc Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Angelini Group, Key Information
Angelini Group, Key Facts
Angelini Group – Pipeline by Indication, 2012
Angelini Group – Pipeline by Stage of Development, 2012
Angelini Group – Monotherapy Products in Pipeline, 2012
Angelini Group – Combination Treatment Modalities in Pipeline, 2012
Angelini Group – Pre-Clinical, 2012
Angelini Group – Pipeline By Therapeutic Class, 2012
Angelini Group - Pipeline By Target, 2012
Angelini Group – Pipeline Products By Mechanism of Action, 2012
Angelini Group - Dormant Developmental Projects,2012
Angelini Group, Other Locations
Angelini Group, Subsidiaries
Angelini Group, Key Manufacturing Facilities
Angelini Group, Deals Summary
Vitaflo Scandinavia Enters Into Distribution Agreement With Angelini Group
Labopharm Forms Joint Venture With Angelini
Angelini Group Enters Into Co-Marketing Agreement With Optimer Pharma For Prulifloxacin
Gruppo Angelini Enters Into Co-Development Agreement With Labopharm
Labopharm Enters Into Licensing Agreement With Angelini Group For OLEPTRO
Labopharm Enters Into Licensing Agreement With Angelini Group For Acetaminophen
Gruppo Angelini Enters Into Licensing Agreement With Labopharm
Labopharm Enters Into Licensing Agreement With Angelini
Helsinn Enters Into Licensing Agreement With ANGELINI FARMACEUTICA
Recordati Signs Licensing Agreement With Angelini
Angelini Group Acquires Faran Labs
Angelini Group Acquires Csc Pharma
LIST OF FIGURES
Angelini Group – Pipeline by Indication, 2012
Angelini Group – Pipeline by Stage of Development, 2012
Angelini Group – Monotherapy Products in Pipeline, 2012
Angelini Group – Combination Treatment Modalities in Pipeline, 2012
Angelini Group – Pipeline By Therapeutic Class, 2012
Angelini Group - Pipeline By Target, 2012
Angelini Group - Pipeline Products By Mechanism of Action, 2012
